Related Experiment Video
Updated: Jul 17, 2026
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
In search of effective anti-HHV-6 agents
Erik De Clercq1, Lieve Naesens
1Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.be
Insights
Developing effective treatments for Human Herpesvirus 6 (HHV-6) is crucial. Researchers are exploring nucleoside and non-nucleoside analogues, alongside protein kinase inhibitors, to combat HHV-6 infections.
Area of Science:
- Virology
- Antiviral Drug Discovery
Background:
- Human Herpesvirus 6 (HHV-6) is a beta-herpesvirus, similar to Human Cytomegalovirus (HCMV).
- Existing anti-HCMV drugs like ganciclovir, foscarnet, and cidofovir are considered for HHV-6 treatment.
- Currently, no specific antiviral drug is established for HHV-6 infections, necessitating further research.
Purpose of the Study:
- To encourage and guide the search for novel antiviral drugs effective against HHV-6.
- To identify potential therapeutic agents for HHV-6-associated diseases.
- To explore different chemical classes of compounds for anti-HHV-6 activity.
Main Methods:
- Investigation of nucleoside analogues, including acyclic derivatives, cyclopropyl nucleosides, and phosphonate analogues.
- Exploration of non-nucleoside analogues such as quinoline-3-carboxamides and aryl sulfones.
- Evaluation of specific protein kinase inhibitors, exemplified by CMV423 targeting protein tyrosine kinases.
Main Results:
- Several nucleoside analogues (e.g., S2242, A-5021, cyclopropavir) show promise.
- Non-nucleoside derivatives offer potential for optimization via structure-activity relationship (SAR) studies.
- CMV423 demonstrates potent and selective activity against HHV-6 by inhibiting cellular protein tyrosine kinases.
Conclusions:
- The development of novel antiviral agents for HHV-6 is actively progressing.
- Both nucleoside and non-nucleoside analogues represent viable strategies for HHV-6 treatment.
- Protein kinase inhibitors are emerging as a promising class of drugs against HHV-6.
Abstract:
Since HHV-6, like HCMV, is a beta-herpesvirus, anti-HCMV drugs such as (val)ganciclovir, foscarnet and cidofovir may, by extrapolation, be advocated for the treatment of HHV-6 infections. At present, no prime candidate for the treatment of HHV-6 infections has been identified or even proposed, which means that the search for antiviral drugs effective against HHV-6-associated diseases should be encouraged. In essence, this search is going into two directions: nucleoside and non-nucleoside analogues. To the first category belong S2242, an N7-substituted purine acyclic derivative; A-5021, a cyclopropyl nucleoside analogue; cyclopropavir, a methylene cyclopropane analogue; lipophilic ester prodrugs of the acyclic nucleoside phosphonate cidofovir; and various other "old" and "new" acyclic nucleoside phosphonate analogues including those derived from the 2, 4-diaminopyrimidine (DAPy) skeleton. To the non-nucleoside category belong a number of quinoline-3-carboxamide, aryl sulfone, benzimidazole riboside and phenylenediamine sulfonamide derivatives which could be further optimized from a structure-activity relationship (SAR) viewpoint so as to specifically target HHV-6 replication. Also, specific protein kinase inhibitors may be pursued as anti-HHV-6 agents, a representative example being the compound CMV423 which, being inhibitory to (cellular) protein tyrosine kinases, exhibits potent and selective activity against HHV-6.
More Related Videos
13:41Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
09:07Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
Published on: August 22, 2019
Related Concept Videos
01:28Herpes
01:22Antiviral Nucleoside Inhibitors